African Swine Fever Virus Protease, a New Viral Member of the SUMO-1-specific Protease Family*

Germán AndrésDagger§, Alí AlejoDagger, Carmen Simón-Mateo, and María L. Salas||

From the Centro de Biología Molecular "Severo Ochoa" (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid), Universidad Autónoma, Cantoblanco, 28049 Madrid, Spain

Received for publication, July 31, 2000, and in revised form, October 9, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

African swine fever virus (ASFV) is a complex DNA virus that employs polyprotein processing at Gly-Gly-Xaa sites as a strategy to produce several major core components of the viral particle. The virus gene S273R encodes a 31-kDa protein that contains a "core domain" with the conserved catalytic residues characteristic of SUMO-1-specific proteases and the adenovirus protease. Using a COS cell expression system, it was found that protein pS273R is capable of cleaving the viral polyproteins pp62 and pp220 in a specific way giving rise to the same intermediates and mature products as those produced in ASFV-infected cells. Furthermore, protein pS273R, like adenovirus protease and SUMO-1-specific enzymes, is a cysteine protease, because its activity is abolished by mutation of the predicted catalytic histidine and cysteine residues and is inhibited by sulfhydryl-blocking reagents. Protein pS273R is expressed late after infection and is localized in the cytoplasmic viral factories, where it is found associated with virus precursors and mature virions. In the virions, the protein is present in the core shell, a domain where the products of the viral polyproteins are also located. The identification of the ASFV protease will allow a better understanding of the role of polyprotein processing in virus assembly and may contribute to our knowledge of the emerging family of SUMO-1-specific proteases.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Positive strand RNA viruses and retroviruses encode polyproteins, which are proteolytically cleaved by viral proteases to yield the nonstructural and structural proteins required for replication and morphogenesis (1-3). On the other hand, DNA viruses, such as adenoviruses and poxviruses, synthesize precursor proteins whose maturation by proteolytic removal of terminal peptides plays an essential role in virion formation (1).

African swine fever virus (ASFV),1 a large and complex virus containing a 170-kb double-stranded DNA molecule with 151 potential genes (4, 5), is atypical among DNA viruses in that it encodes two polyproteins, pp220 and pp62, which are cleaved to produce six major structural components of the virus particle (6, 7). These proteins, p150, p37, p34, and p14, derived from polyprotein pp220 and p35 and p15, products of polyprotein pp62, are the major components of the core shell, a thick protein layer that surrounds the DNA-containing central nucleoid and that is enwrapped by the inner lipoprotein envelope and the icosahedral capsid (8).2 All the proteolytic cleavages occur after the second Gly of the consensus sequence Gly-Gly-Xaa, which is also recognized as a cleavage site in the maturation of adenovirus structural proteins and in some cellular proteins, including polyubiquitin (9) and ubiquitin-like proteins (10). A similar cleavage site (Ala-Gly-Xaa) is used for the maturation of vaccinia virus structural proteins (11, 12). Although the adenovirus protease that processes at Gly-Gly-Xaa sites is well characterized (13-15), the enzymes involved in the processing of the ASFV polyproteins or in the cleavage of vaccinia virus precursor proteins have not yet been identified.

Recently, Li and Hochstrasser (16) have described a novel cysteine protease from yeast, designated Ulp-1, that catalyzes the release of the ubiquitin-like protein SUMO-1/Smt3 from its precursor or from sumoylated proteins, with the cleavage taking place at Gly-Gly-Xaa sequences. Since the publication of this report, other SUMO-1-specific proteases similar to the yeast enzyme have been identified in vertebrates (17-19). These proteases would regulate the SUMO-1-modified state of certain proteins whose function in a variety of cellular processes, such as cell cycle progression and nuclear import, is dependent on this modification (20). Li and Hochstrasser (16) have also shown that a "core domain" of ~90 amino acids of the yeast protease, containing the conserved catalytic cysteine and histidine residues, presents some similarity to gene products from several animal viruses, including the adenovirus L3 protease, the I7 products of fowlpox and vaccinia virus, and open reading frame (ORF) S273R of ASFV. This suggested that the S273R product might be the protease involved in the processing of the ASFV polyproteins. We show here, using an expression system in COS cells, the specific processing of polyproteins pp62 and pp220 in the presence of protein pS273R. Furthermore, inhibitor profiling and site-directed mutagenesis results indicate that this protein is a cysteine protease. Studies on the synthesis and localization of protein pS273R during ASFV infection are also presented. The results are consistent with a role for the virus protease in the assembly of the virus core.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells and Viruses-- Vero and COS-7 cells were obtained from the American Type Culture Collection and grown in Dulbecco's modified Eagle's medium containing 5% fetal calf serum. The Vero-adapted ASFV strain BA71V was propagated and titrated as described previously (21). Highly purified ASFV was prepared as described (22). The recombinant vaccinia virus vTF7-3 expressing bacteriophage T7 RNA polymerase (23) was kindly donated by Dr. B. Moss.

Plasmids and Site-directed Mutagenesis-- Plasmid pRSET-S273R carrying the ASFV S273R gene as an N-terminal hexahistidine fusion was obtained as follows. The S273R gene was amplified by polymerase chain reaction using oligonucleotides 273-PCR1 (5'-CGCGCGCTCGAGATGTCTATATTAGAAAAAATTACGT) and 273-PCR2 (5'-GCGCGCGAATTCTTATGCGATGCGAAACAGATGGGT), digested with XhoI and EcoRI, and cloned into the pRSET-A vector (Invitrogen).

The S273R gene was subcloned from pRSET-S273R into the T7 promoter containing mammalian expression vector pcDNA 3.1 (Invitrogen), and the recombinant plasmid pcDNA-S273R was used for activity assays in transfection experiments. Site-directed mutagenesis of the S273R gene was performed by polymerase chain reaction (24) using as a template the pcDNA-S273R plasmid. The histidine residue at position 168 was mutated to arginine (S273R,H168R mutant) and cysteine 232 was mutated to serine (S273R,C232S mutant). Amplified mutant fragments corresponding to the complete S273R gene were cloned into the pcDNA 3.1 vector, and the presence of the desired mutation and absence of additional changes were confirmed by sequencing of the resulting plasmids. The recombinant plasmid KS-CP530R containing ORF CP530R, which encodes the pp62 polyprotein of 530 amino acids under the control of the T7 polymerase promoter, was obtained as described (7).

The plasmid KS-p17C'f, used for the generation of antibodies against both polyprotein pp62 and its mature p35 product, was obtained as follows. The plasmid KS-CP530R was digested with PstI, blunted with Mung Bean exonuclease, and then digested with Mlu I and filled in with Klenow fragment. After ligation, this recombinant plasmid lacks the region spanning amino acid residues 15-175 of pp62 polyprotein. This plasmid was again digested with XhoI to remove the 3' end of ORF CP530R spanning amino acid residues 343-530.

Plasmid pGEM-CP2475L was constructed by cloning the 0.7-kb XbaI/PstI fragment from plasmid pAR-p34 (6) and the 6.9-kb PstI/XbaI fragment of the RC' restriction fragment of the ASFV genome (5) into vector pGEM-4 (Promega). The resulting plasmid contained the complete CP2475L ORF, encoding polyprotein pp220, under the control of the T7 polymerase promoter.

Antibodies-- To prepare antibodies against protein pS273R, Escherichia coli BL21(DE3) pLysS cells harboring the pRSET-S273R plasmid were induced for 1.5 h with 0.4 mM isopropyl-beta -D-thiogalactopyranoside, and the recombinant protein was purified under denaturing conditions using single-step Ni2+-nitrilotriacetic acid affinity chromatography. Antibodies against the purified recombinant pS273R protein were raised in rabbits.

The mouse monoclonal antibody 18H.H7, which recognizes both the ASFV polyprotein pp220 and its mature product p150, was used in the immunofluorescence studies. This antibody, as well as the rabbit polyclonal anti-p150, anti-p34, and anti-p37/p14 sera, which also recognize polyprotein pp220, have been previously characterized (6, 8, 25).

The rabbit polyclonal serum against proteins pp62 and p35 was raised against the 17-kDa recombinant protein encoded by plasmid KS-p17C'f. For this, KS-p17C'f transformed E. coli BL21(DE3) cells were induced for 2 h with 1 mM isopropyl-beta -D-thiogalactopyranoside and then incubated for 2 h with rifampicin (0.2 mg/ml). After lysis and centrifugation, the pellet containing the recombinant protein as the main component was used to generate antibodies in rabbits. The rabbit polyclonal serum against ASFV polyprotein pp62 and its mature product p15 has already been described (7).

Coexpression Experiments-- COS-7 cells were transfected with 250 ng of DNA/105 cells of the plasmids indicated in each case using LipofectAMINE Plus reagent (Life Technologies, Inc.) following the manufacturer's indications for 1 h at 37 °C. In cotransfection experiments, the amount of pcDNA-S273R was <FR><NU>1</NU><DE>10</DE></FR> of that of the polyprotein gene-containing plasmid. Subsequently, the cells were infected with vTF7-3 at a multiplicity of infection of 5 plaque-forming units/cell, allowing the expression of T7 RNA polymerase and thus of the polyprotein and S273R genes. The infection was carried out in the presence of 40 µg/ml cytosine arabinoside to inhibit vaccinia virus late protein synthesis. The expression and processing of the polyprotein was analyzed at 16 h post-infection by Western blot, as indicated below.

Preparation of Polyprotein or Protease-containing Extracts and in Vitro Assay of Processing Activity-- COS-7 cells were transfected/infected as described before using the corresponding plasmids. At 16 h post-infection, the cells were resuspended at 107 cells/ml in homogenization buffer containing 20 mM HEPES, pH 7.4, 0.28 M sucrose, 2 mM EDTA, and passed through a 25-gauge syringe 15 times. The homogenate was centrifuged at 700 × g for 5 min to sediment nuclei and unbroken cells, and the supernatant fraction was subsequently centrifuged at 100,000 × g for 30 min at 4 °C to separate the soluble cytoplasm from the membrane/particulate material. The activity assays in vitro were performed using the soluble cytoplasmic fraction as source of protein pS273R and polyprotein pp62 and the membrane/particulate cytoplasmic fraction as a source of polyprotein pp220. Reactions were performed at 30 °C in a final volume of 50 µl containing 5 µl of both protease and polyprotein-containing extracts diluted in 20 mM HEPES, pH 7.4. After the indicated times, the samples were subjected to SDS-polyacrylamide gel electrophoresis and analyzed by immunoblotting.

For inhibitor studies, the reactions were incubated for 6 h as above in the absence or in the presence of the following protease inhibitors: 10 µM pepstatin, 1 mM 1,10-phenanthroline, 1 mM phenylmethanesulfonyl fluoride, 2.5 mM N-ethylmaleimide, 100 µM benzyloxycarbonyl-leucyl-valyl-glycyl-diazomethylketone (Z-LVG-CHN2), or 100 µM L-trans-epoxysuccinyl-leucylamide-(4-guanidino)-butane (E-64). All the inhibitors were freshly prepared as a 100-fold concentrated stock solution in methanol with the exception of Z-LVG-CHN2 and E-64, prepared in dimethyl sulfoxide and water, respectively.

Western Blot Analysis-- For Western blots, equivalent amounts of whole cell extracts or cytosolic fractions were electrophoresed on SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were incubated with a 1:1,000 dilution of the antibodies and then with a 1:10,000 dilution of peroxidase-labeled anti-rabbit serum (Amersham Pharmacia Biotech), and the proteins were detected with the ECL system (Amersham Pharmacia Biotech) according to the manufacturer's recommendations.

Preparation and Analysis of RNA-- Vero cells were mock-infected or infected with ASFV (BA71V strain) at a multiplicity of 20 plaque-forming units/cell. To obtain early RNA, the cells were infected in the presence of 100 µg/ml cycloheximide or 40 µg/ml cytosine arabinoside for 7 h. Late RNA was isolated from cells infected for 18 h in the absence of inhibitors. Whole cell RNA was prepared by the guanidinium isothiocyanate/cesium chloride extraction procedure (26), and poly (A)+ RNA was selected by oligo (dT)-cellulose chromatography as described by Sambrook et al. (27). Northern blot hybridization was carried out as reported elsewhere (28) with 2 µg of each class of poly (A)+ RNA, using as probe the 32P-end-labeled oligonucleotide S273R (5'-TACTTAAACAGCTATCTTTGTTTGTAAGGT), complementary to nucleotides +79 to +50 of gene S273R. Primer extension analysis was performed essentially as described by Sambrook et al. (27). After 5' end-labeling with 32P, the oligonucleotide S273R was annealed at 30 °C to the different classes of RNA and extended with avian myeloblastosis virus reverse transcriptase for 2 h at 42 °C. The primer extension products were then electrophoresed in a 6% polyacrylamide gel alongside an irrelevant DNA sequence reaction.

Immunofluorescence Microscopy-- Vero cells grown on coverslips were mock-infected or infected with ASFV at a multiplicity of infection of 1 plaque-forming unit/cell and fixed at 18 h post-infection with methanol at -20 °C for 5 min. The cells were incubated with a 1:250 dilution of rabbit polyclonal anti-pS273R serum and a 1:10 dilution of mouse monoclonal (18H.H7) anti-pp220 antibody as indicated in the legend to Fig. 5 and incubated for 45 min at 37 °C with a 1:500 dilution of Alexa 488 goat anti-rabbit IgG and a 1:500 dilution of Alexa 594 goat anti-mouse IgG antibodies (Molecular Probes, Inc.). As a control, each antibody was individually tested. Cells were examined with an Axiovert fluorescent microscope (Carl Zeiss, Inc.).

Immunoelectron Microscopy-- Vero cells were infected with ASFV at a multiplicity of infection of 10 plaque-forming units/cell and fixed, at 20 h post-infection, with 4% formaldehyde and 0.1% glutaraldehyde in 200 mM HEPES, pH 7.2, for 1 h at room temperature. After fixation, the cells were processed for cryosectioning as detailed by Andrés et al. (29). Ultrathin thawed cryosections were incubated for 45 min at room temperature with a 1:10 dilution of the anti-pS273R antibody followed by an incubation of 30 min at room temperature with a 1:40 dilution of protein A-gold (diameter, 10 nm; Biocell Research Laboratories). Specimens were examined with a Jeol 1010 microscope.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Polyprotein Processing Activity of Protein pS273R-- To investigate the putative protease activity of protein pS273R, we have used a system of COS-7 cells transiently coexpressing the S273R gene and the genes coding for polyprotein pp62 and polyprotein pp220, which served as substrates. During ASFV infection, polyprotein pp62 is first cleaved at a Gly-Gly-Gly sequence at positions 157-159 to produce the 15-kDa structural protein p15 and an intermediate precursor of 46 kDa (pp46). A second cleavage at the Gly-Gly-Asn site at positions 462-464 gives rise to the mature structural protein p35 of 35 kDa and to an 8-kDa polypeptide that has not been detected in the infected cells (7) (Fig. 1A, upper diagram). An alternative, although minor, processing pathway, described in the lower diagram of Fig. 1A, has also been found.2 In this case, processing first takes place at the most C-terminal cleavage site, producing an intermediate pp52 precursor of 52 kDa. Cleavage of this intermediate at the Gly-Gly-Gly sequence at position 157-159 then produces the two structural proteins p15 and p35.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Proteolytic processing of pp62 polyprotein by protein pS273R. A, schematic representation of polyprotein pp62 processing. The two alternative processing pathways are shown. The precursor proteins are indicated by white boxes, and mature products are shown by black boxes. The cleavage sites are indicated by arrowheads. B, COS-7 cells were transfected with KS and pcDNA 3.1 plasmids containing the pp62 and S273R genes, respectively, and infected with vTF7-3 as indicated under "Experimental Procedures." 16 h after infection, expression of the transfected genes was analyzed by Western blot, using antibodies against proteins p35 (upper panel), p15 (middle panel), or pS273R (lower panel). Lanes 1, not infected and not transfected cells; lanes 2, cells infected but not transfected; lanes 3, cells infected and transfected with pp62 gene; lanes 4, cells infected and cotransfected with genes pp62 and S273R; lanes 5, 0.5 µg of highly purified ASFV. The bands corresponding to polyprotein pp62 and its proteolytic products and to protein pS273R are indicated on the right. The migration position of molecular mass markers is indicated on the left. C, time course of polyprotein pp62 processing by protein pS273R in vitro. Cytosolic extracts containing pp62 or pS273R proteins, prepared as described under "Experimental Procedures," were mixed and incubated for 15 min (lanes 2), 1 h (lanes 3), or 3 h (lanes 4). As a control, the extract containing polyprotein pp62 alone was incubated for 6 h (lanes 1). Polyprotein processing was analyzed by Western blot using anti-p35 (upper panel) or anti-p15 (lower panel) antibodies. The bands corresponding to polyprotein pp62 and its products are indicated on the right.

As shown in Fig. 1B (lanes 3 of top and middle panels), a specific band corresponding to the unprocessed pp62 polyprotein was detected by Western blot using both anti-p35 and anti-p15 antibodies in lysates from cells transfected with the polyprotein gene and infected with vTF7-3. When the polyprotein was coexpressed with the S273R gene (Fig. 1B, top and middle panels, lanes 4), the pp62 band strongly decreased coinciding with the appearance of the proteolytic products p35 (upper panel) and p15 (middle panel), which had the same electrophoretic mobility as the structural proteins p35 and p15 detected in the samples of highly purified ASFV (Fig. 1B, top and middle panels, lanes 5). In addition, the pp46 intermediate could be detected with the anti-p35 serum, whereas the antibody against protein p15 revealed a specific band of 52 kDa, which probably corresponds to pp52 precursor. The expression of gene S273R in the transfected cells is shown in the lower panel of Fig. 1B. The protein had a size of 31 kDa, which is consistent with its predicted molecular weight of 31,550 (30). As shown in Fig. 1B (bottom panel, lane 5), protein pS273R was also detected in purified virus particles.

To assay the activity of protein pS273R in vitro, cytosolic extracts from COS-7 cells expressing protein pS273R or polyprotein pp62, prepared as described under "Experimental Procedures," were mixed and incubated for varying time periods, as indicated in Fig. 1C. After incubation, the samples were analyzed by Western blot using antibodies against proteins p35 (upper panel) or p15 (lower panel). Fig. 1C shows that in the presence of pS273R polyprotein pp62 is processed in a time-dependent and cascade fashion, with the formation of pp52 and pp46 intermediates, which are converted to the mature p35 and p15 products. As can also be seen in this figure, the p15 product, detected at the earliest time examined (15 min), increased at 1 h, and remained constant at later times, whereas the amount of the mature protein p35 increased considerably from 1 to 3 h of incubation. These results suggest that, as it occurs during ASFV infection (7), the main initial event in the in vitro processing of pp62 by protein pS273R is the recognition of the cleavage site at position 158-159, with the formation of the mature p15 protein and preprotein pp46. This latter protein would then be cleaved at positions 463-464 to produce the mature protein p35.

A similar in vitro assay was performed to analyze whether protein pS273R was also able to cleave polyprotein pp220 into its mature products. During ASFV infection, polyprotein pp220 is firstly cleaved at the Gly-Gly-Gly sequence at positions 43-45 and the Gly-Gly-Ala sequence at positions 892-894 to give rise to the mature product p150 and the intermediate precursor protein pp90 (6) (Fig. 2A). Preprotein pp90 is subsequently cleaved at a Gly-Gly-Asp sequence at positions 367-369 to generate the mature protein p34 and the intermediate precursor pp55, which is finally processed at a Gly-Gly-Ala site at positions 521-523 to produce the mature products p14 and p37. As shown in Fig. 2B (lanes 1), the antibodies against products p150 (top panel), p34 (middle panel), and p37 and p14 (bottom panel) detected the unprocessed pp220 polyprotein in pp220 containing extracts incubated for 6 h in the absence of protein pS273R. Additionally, lower molecular weight bands, probably corresponding to incomplete forms of the pp220 polyprotein produced in the transfected cells, were observed. After incubation with pS273R containing extracts for 1 h (lanes 2), 3 h (lanes 3), and 6 h (lanes 4), the levels of polyprotein pp220 decreased in a time-dependent fashion coinciding with the appearance and accumulation of proteins of 150 kDa (upper panel), 34 kDa (middle panel), and, more weakly, of 37 kDa, which was only visualized after a longer exposure time (lower panel). These proteolytic products comigrated with the mature proteins p150, p34, and p37 present in samples of purified ASFV particles (lanes 5). Interestingly, a 90-kDa protein was also specifically detected by the antibodies against protein p34 (middle panel, lanes 2-4) and proteins p37/p14 (lower panel, lanes 2-4), whereas a 55-kDa protein was recognized only by the anti-p37/p14 serum (lower panel, lanes 2-4). The detection of these proteins is consistent with the formation of the intermediate precursors pp90 and pp55 (Fig. 2A). The other mature product p14 could not be detected in the in vitro assays because of the poor recognition of protein p14 by Western blot analysis (see lane 5 in the lower panel) and, possibly, because of a low efficiency of processing of precursor pp55. These results indicate that the two ASFV polyproteins pp220 and pp62 are accurately cleaved in the presence of protein pS273R to give rise to the same mature products and intermediate precursors as those produced during ASFV infection.



View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2.   Proteolytic processing of pp220 polyprotein by protein pS273R. A, schematic representation of polyprotein pp220 processing during ASFV infection. The precursor proteins are indicated by white boxes, and mature products are indicated by black boxes. The cleavage sites are indicated by arrowheads. B, time course of polyprotein pp220 processing by protein pS273R in vitro. COS-7 cells were transfected with pGEM and pcDNA 3.1 plasmids containing the pp220 and S273R genes, respectively, and infected with vTF7-3 as indicated under "Experimental Procedures." Membrane/particulate extracts, containing pp220 protein, and cytosolic extracts, containing pS273R protein, prepared as indicated under "Experimental Procedures," were mixed and incubated for 1 h (lanes 2), 3 h (lanes 3), and 6 h (lanes 4). As a control, the extract containing polyprotein pp220 alone was incubated for 6 h (lanes 1). Polyprotein processing was analyzed by Western blot using anti-p150 (top panel), anti-p34 (middle panel), and anti-p37/p14 (bottom panel) antibodies. A longer exposure of the region corresponding to protein p37 is shown in a separate box in the bottom panel. Lanes 5 show the migration of structural proteins p150, p34, and p37 from 0.5 µg of highly purified ASFV. The bands corresponding to polyprotein pp220 and its products are indicated on the right. Note that the anti-p37/p14 serum (bottom panel) did not detect protein p14 neither in the in vitro assay (lanes 2-4) nor in the virus sample (lane 5). Molecular masses are indicated on the left.

Characterization of Protein pS273R as a Cysteine Protease-- As reported by Li and Hochstrasser (16) and shown in the alignment of Fig. 3A, the ASFV protein pS273R conserves near its C terminus the catalytic core domain of the SUMO-1-specific proteases and the adenovirus protease containing the four key catalytic residues, His, Glu/Asp (Asn in the case of the ASFV protein), Gln, and Cys, which are characteristic of cysteine proteases. To investigate whether the ASFV protein was also a cysteine protease, a number of inhibitors specific for the different classes of proteases were tested using the in vitro assay described above. As shown in Fig. 3B, inhibitors of aspartic proteases (pepstatin), metallo-proteases (1,10-phenanthroline), or serine proteases (phenylmethanesulfonyl fluoride) had no effect on pp62 processing. On the other hand, two cysteine protease inhibitors, N-ethylmaleimide and the peptidyl diazomethane Z-Leu-Val-Gly-CHN2, completely or partially blocked, respectively, the cleavage of the polyprotein. It is of interest to note that E-64, which is also a specific inhibitor of cysteine proteases, did not inhibit the processing activity of protein pS273R. In this connection, it should be mentioned that the adenovirus protease is also relatively insensitive to this compound (31, 32).



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   Characterization of protein pS273R as a cysteine protease. A, sequence alignment of the conserved catalytic core domain of protein pS273R and members of the SUMO-1-specific protease family. Multiple alignment of 15 sequences was performed online by using the CLUSTALW program (42) at the European Bioinformatics Institute. The alignment of five selected sequences is presented in the figure. Numbers at left and right indicate the amino acid position relative to the N terminus of each protein. Residues conserved or identical in at least 80% of the 15 sequences aligned are in bold type over a gray background. The invariant residues in the 15 sequences are indicated with an asterisk. Full triangles mark the amino acid residues of the catalytic triad (His, Asn/Asp/Glu, and Cys) and the Gln residue involved in the formation of the oxyanion hole in the active site. Sequences: ASFV S273R, protein pS273R of ASFV (Q00946); VACCV I7, vaccinia virus I7 protein (P12926); ADE2 VPRT, human adenovirus 2 protease (P03252); SENP1 Hs, human sentrin-specific protease (AF149770); Ulp1 Sc, Saccharomyces cerevisiae Ulp1 protease (S63462). B, effect of protease inhibitors on the processing of pp62. Cytosolic extracts containing polyprotein pp62 or protein pS273R were mixed and incubated for 6 h at 30 °C in the absence (- lanes) or presence of 10 µM pepstatin (Peps), 1 mM 1,10-phenanthroline (Phen), 1 mM phenylmethanesulfonyl fluoride (PMSF), 2.5 mM N-ethylmaleimide (NEM), 100 µM Z-LVG-CHN2 (LVG), or 100 µM E-64. A control reaction containing the proteolytic substrate pp62 alone is also presented (-). The samples were then analyzed by Western blot using an anti-p35 antibody. The pp62 and p35 bands are indicated. C, assay of processing activity of S273R-C232S and S273R-H168R mutants. Processing activity was determined as in B after incubation of polyprotein pp62 alone (-), or with wild type S273R (wt), S273R-C232S (C232S), or S273R-H168R (H168R). Western blot analysis of reaction products and protein pS273R was performed using anti-p35 and anti-pS273R antibodies, respectively. The bands corresponding to pp62, p35, and pS273R are indicated.

To further characterize the pS273R protein as a cysteine protease, the conserved cysteine and histidine residues of the putative catalytic domain were mutated to serine and arginine, respectively, and the activity of the mutant proteins was tested. As shown in Fig. 3C, no cleavage was detected with the pS273R-C232S or pS273R-H168R mutants, indicating that the conserved cysteine and histidine residues are indeed critical for the activity of protein pS273R.

Expression of Gene S273R in ASFV-infected Vero Cells-- To study the transcription of gene S273R during ASFV infection, RNA hybridization and primer extension analysis were carried out with the 32P-labeled oligonucleotide S273R (see "Experimental Procedures") specific for ORF S273R. Hybridization of this oligonucleotide to Northern blots containing RNA from mock-infected cells and early (cycloheximide and cytosine arabinoside) and late RNA from cells infected with ASFV showed a main band of 4.5 kb, as well as other species, in the late RNA sample (Fig. 4A). Primer extension analysis revealed a main band of 93 nucleotides that was detected only in the case of the late RNA sample (Fig. 4B) and corresponded to initiation of transcription at position -15 relative to the first nucleotide of the translation start codon of ORF S273R. A motif composed of seven or more consecutive thymidylate residues (the 7T motif) has been identified as a signal for 3'-end formation of ASFV mRNAs (33). The first 7T motif after ORF S273R is found 52 nucleotides downstream of the contiguous P1192R ORF coding for the virus topoisomerase II (30). Termination of transcription at this motif would produce an RNA of 4497 bases, which is consistent with the size of the main RNA band detected by Northern blot.



View larger version (43K):
[in this window]
[in a new window]
 
Fig. 4.   Expression of gene S273R in ASFV-infected Vero cells. A, Northern blot analysis of RNA from mock-infected cells (M), early RNA from cells infected with ASFV in the presence of cycloheximide (C) or cytosine arabinoside (A), and late RNA from cells infected in the absence of inhibitors (L). The arrow indicates the 4.5-kb RNA band corresponding to the S273R gene. B, primer extension analysis of the 5' end of S273R transcripts. The same classes of RNA were used. After extension, the samples were electrophoresed beside an irrelevant DNA sequencing reaction (DNA ladder). The size of the major DNA fragment obtained is indicated. C, Western blot analysis with the anti-pS273R antibody was carried out for mock-infected cells (lane 1) or ASFV-infected cells harvested at 4 (lane 2), 8 (lane 3), 10 (lane 4), 12 (lane 5), 14 (lane 6), and 20 (lane 7) h post-infection. Results obtained with cells infected for 20 h in the presence of cytosine arabinoside (lane 8) and with 2 µg of highly purified ASFV particles (lane 9) are also shown. The migration positions of molecular mass markers are shown on the left. The band corresponding to protein pS273R is indicated on the right.

Western blot analysis revealed the presence of a specific band migrating at the expected position for protein pS273R (31 kDa) in ASFV-infected cells (Fig. 4C). This band was first detected at 8 h post-infection, a time at which viral DNA replication in Vero cells is already underway (34), and accumulated up to 20 h post-infection. Furthermore, the protein band was not seen in the presence of cytosine arabinoside, an inhibitor of viral DNA replication and late transcription, indicating that protein pS273R is a late protein. As can also be seen in this figure, protein pS273R synthesized in the infected cells comigrated with that present in purified virus particles (Fig. 4C, lane 9).

Localization of Protein pS273R in Infected Cells-- To study the intracellular localization of pS273R protein, mock-infected and ASFV-infected Vero cells were fixed at 18 h after infection and analyzed by immunofluorescence with the anti-pS273R serum. As shown in Fig. 5A, a low background signal was observed in the mock-infected cells used as a control. In contrast, the antibody against protein pS273R strongly stained discrete cytoplasmic areas of the virus-infected cells (Fig. 5B), which were identified as virus factories by immunolabeling with a monoclonal antibody that recognizes the polyprotein precursor pp220 and its mature product p150 (Fig. 5C) (8). As previously reported, the antibody to pp220/p150 proteins also labeled virus particles scattered throughout the cytoplasm (8). Although more weakly, the anti-pS273R serum also stained cytoplasmic clusters of virions outside the assembly areas (Fig. 5B), suggesting that protein pS273R is incorporated into the virus particles, in agreement with the immunoblotting experiments performed with purified virions.



View larger version (61K):
[in this window]
[in a new window]
 
Fig. 5.   Immunfluorescence detection of protein pS273R in Vero cells infected with ASFV. Mock-infected (A) or ASFV-infected (B and C) Vero cells were fixed at 18 h post-infection and double-labeled with anti-pS273R antibody detected with Alexa 488 goat anti-rabbit IgG (A and B) and with anti-pp220 monoclonal antibody detected with Alexa 594 goat anti-mouse IgG (C). In B and C, the viral factories and clusters of virions, labeled with both antibodies, are indicated by arrows and arrowheads, respectively.

To examine in more detail the localization of ASFV protease within the virus factories, we carried out an immunoelectron microscopic analysis of Vero cells infected with ASFV for 20 h. For this, thawed cryosections were incubated with the anti-pS273R antibody followed by protein A-gold. As shown in Fig. 6A, the antibody labeled the region of the viral factories, in keeping with the immunofluorescence results. Within the assembly sites, labeling was essentially associated with both intermediate virus structures (Fig. 6B) and mature virions (Fig. 6C). Interestingly, gold grains were localized within the core region of immature icosahedral particles that lack the electron dense DNA-containing nucleoid. Within mature particles, the signal was associated with the core shell (Fig. 6C), the protein domain surrounding the electron dense nucleoid and containing the polyprotein products (8).



View larger version (138K):
[in this window]
[in a new window]
 
Fig. 6.   Immunoelectron microscopy with anti-pS273R serum in ASFV-infected Vero cells. Vero cells were infected with ASFV, fixed at 20 h post-infection, and processed for cryosectioning. Ultrathin sections were incubated with the anti-pS273R antibody followed by protein A-gold (10 nm) as described under "Experimental Procedures." A, section of an infected cell showing a region of the cytoplasm containing a viral factory (VF). B and C, regions of a viral factory at a higher magnification. In B, the labeling is associated with the core region of immature virus particles (arrows). In C, gold particles are localized in the core shell of mature virions (arrows). The core shell domain is delimited in the right upper virus. Bars, 100 nm.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A new family of structurally related cysteine proteases that process SUMO-1-modified proteins at consensus Gly-Gly-Xaa sequences has been recently described (16). The sequence similarity between the members of this family is largely confined to a C-terminal region of about 200 amino acids that contains a 90-amino acid core domain that is also present in the adenovirus protease, as well as in the poxvirus I7 protein and protein pS273R of ASFV. This core domain contains the active site triad of the adenovirus protease, composed of residues His54, Glu71, and Cys122, which in the crystal structure of this enzyme have a spatial disposition identical to that of the catalytic triad of the classical cysteine protease papain (35), although the sequential order of the residues in the polypeptide chain of this enzyme is Cys25, His159, and Asn175. In addition, a fourth residue, Gln115, of the adenovirus protease is in an equivalent spatial position to the Gln19 of papain involved in the formation of the oxyanion hole in the active site. The ASFV protein pS273R conserves the His, Cys, and Gln residues, and, as in the case of papain, has an Asn at the position of the adenovirus protease Glu71 residue. This sequence similarity strongly argued that this protein was the protease implicated in the proteolytic processing of ASFV polyproteins at Gly-Gly-Xaa sites.

The results presented here show that protein pS273R processes the virus polyproteins in a specific and accurate way giving rise to the same intermediates and final mature products as those produced in ASFV-infected cells, suggesting that this protein is the protease involved in polyprotein processing during the infection. Furthermore, and as expected from the sequence comparison, the protein has been characterized as a cysteine protease, because its activity is abrogated by mutation of the critical His and Cys residues of the conserved catalytic domain and is inhibited by sulfhydryl-blocking reagents.

Taking into account the above findings, the ASFV protease can be included in the same group of cysteine proteases as the SUMO-1-specific proteases and the protease from adenovirus. All of these proteins are characterized by the presence of unrelated N-terminal extensions of variable lengths, which most likely account for the specificity of the substrate. In relation to this, it is worth noting that the ASFV protease is the only enzyme of this group that processes polyprotein precursors recognizing several Gly-Gly-Xaa sites in the substrate sequence. Interestingly, during ASFV infection, this processing occurs through an ordered cascade of proteolytic cleavages, which may depend on conformational changes in the intermediate products or on interaction with other proteins during virus morphogenesis (6, 7). The identification of the viral protease will help to elucidate the mechanisms underlying the cascade processing of the viral polyproteins. It is also possible that the viral enzyme might be able to cleave cellular or viral ubiquitin-like modified proteins. This is an interesting possibility that may provide insight into the structural and functional aspects of this emerging family of cysteine proteases.

The studies on the expression and localization of protein pS273R in cells infected with ASFV further support a role for this protein in the processing of the viral polyproteins during the virus morphogenesis. Thus, protein pS273R, as its polyprotein substrates, is synthesized at late times of infection and is localized within the cytoplasmic viral factories where morphogenesis occurs.

We have previously shown that the mature proteins p150, p37, p34, and p14, products of polyprotein pp220, are major components of the core shell, representing about 25% of the total protein mass of the virus particle (8). The same location has been found for the structural proteins p35 and p15, which are derived from polyprotein pp62.2 These findings, together with the observed localization of protein pS273R in the virus morphogenetic intermediates, suggest a role for the ASFV protease in the assembly of the viral core. Thus, proteolytic processing might be an essential mechanism for the spatio-temporal control of the interactions between core components, in such a way that only preassembled and properly processed substrates could enter the assembly pathway. In connection with this, it should be mentioned that other complex DNA-containing viruses, such as adenoviruses and poxviruses, use proteolytic processing at similar or identical cleavage sequences for the maturation of major core proteins. In the case of poxviruses, the cleavage of core precursors is crucial for the formation of virus particles, which does not take place if the processing is blocked (36). In contrast, the adenovirus protease acts in newly assembled virions, being needed for their maturation into infectious virions (37). To ensure that processing of the viral precursor proteins takes place only after virion assembly, this enzyme employs a unique and complex regulatory mechanism, involving stimulation of its activity by peptide and DNA cofactors (13, 14). Further studies will be needed to ascertain whether similar mechanisms operate to control the temporal and spatial activity of the ASFV protease.

As has also been described for the adenovirus protease and the I7 protein of poxviruses (38, 39), the ASFV protein pS273R is present in the core of mature virus particles. This finding could merely reflect a residual presence of an enzymatic activity needed during the final steps of ASFV morphogenesis. Another possibility is that protein pS273R is involved in some early event of viral infection. This is the case for the adenovirus protease that has been implicated in virus entry into the host cell and disassembly of the incoming virus particles (40, 41). Whether the ASFV protease, besides a morphogenetic role late in the virus replicative cycle, might also cleave other viral or even cellular substrates early in infection is a question that remains to be addressed.


    ACKNOWLEDGEMENTS

We thank J. Salas and C. López-Otín for critical reading of the manuscript.


    FOOTNOTES

* This work was supported by Dirección General de Investigación Científica y Técnica Grant PB96-0902-C02-01, European Community Grant FAIR5-CT97-3441, Ministerio de Educación y Cultura Grant AGF98-1352-CE, and an institutional grant from the Fundación Ramón Areces.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger The first two authors contributed equally to this work.

§ Fellow of the Comunidad Autónoma de Madrid.

Present address: Centro Nacional de Biotecnología (CSIC), Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain.

|| To whom correspondence should be addressed: Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain. Tel.: 34-913978478; Fax: 34-913974799; E-mail: mlsalas@cbm.uam.es.

Published, JBC Papers in Press, October 12, 2000, DOI 10.1074/jbc.M006844200

2 G. Andrés, unpublished results.


    ABBREVIATIONS

The abbreviations used are: ASFV, African swine fever virus; kb, kilobase(s); ORF, open reading frame; Z-LVG-CHN2, benzyloxycarbonyl-leucyl-valyl-glycyl-diazomethylketone; E-64, L-trans-epoxysuccinyl-leucylamide-(4-guanidino)-butane.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Kräusslich, H.-G., and Wimmer, E. (1988) Annu. Rev. Biochem. 57, 701-754[CrossRef][Medline] [Order article via Infotrieve]
2. Dougherty, W. G., and Semler, B. L. (1993) Microbiol. Rev. 57, 781-822[Abstract]
3. Gorbalenya, A. E., and Snijder, E. J. (1996) Persp. Drug Discov. Design 6, 64-86
4. Viñuela, E. (1985) Curr. Top. Microbiol. Immunol. 116, 151-170[Medline] [Order article via Infotrieve]
5. Yáñez, R. J., Rodríguez, J. M., Nogal, M. L., Yuste, L., Enríquez, C., Rodriguez, J. F., and Viñuela, E. (1995) Virology 208, 249-278[CrossRef][Medline] [Order article via Infotrieve]
6. Simón-Mateo, C., Andrés, G., and Viñuela, E. (1993) EMBO J. 12, 2977-2987[Abstract]
7. Simón-Mateo, C., Andrés, G., Almazán, F., and Viñuela, E. (1997) J. Virol. 71, 5799-5804[Abstract]
8. Andrés, G., Simón-Mateo, C., and Viñuela, E. (1997) J. Virol. 71, 2331-2341[Abstract]
9. López-Otín, C., Simón-Mateo, C., Martínez, L., and Viñuela, E. (1989) J. Biol. Chem. 264, 9107-9110[Abstract/Free Full Text]
10. Kamitani, T., Nguyen, H. P., and Yeh, E. T. H. (1997) J. Biol. Chem. 272, 14001-14004[Abstract/Free Full Text]
11. VanSlyke, J. K., Whitehead, S. S., Wilson, E. M., and Hruby, D. E. (1991) Virology 183, 467-478[Medline] [Order article via Infotrieve]
12. Lee, P., and Hruby, D. E. (1994) J. Biol. Chem. 269, 8616-8622[Abstract/Free Full Text]
13. Webster, A., Hay, R. T., and Kemp, G. (1993) Cell 72, 97-104[Medline] [Order article via Infotrieve]
14. Mangel, W. F., Toledo, D. L., Brown, M. T., Martin, J. H., and McGrath, W. J. (1996) J. Biol. Chem. 271, 536-543[Abstract/Free Full Text]
15. Ding, J., McGrath, W. J., Sweet, R. M., and Mangel, W. F. (1996) EMBO J. 15, 1778-1783[Abstract]
16. Li, S.-J., and Hochstrasser, M. (1999) Nature 398, 246-251[CrossRef][Medline] [Order article via Infotrieve]
17. Suzuki, T., Ichiyama, A., Saitoh, H., Kawakami, T., Omata, M., Chung, C. H., Kimura, M., Shimbara, N., and Tanaka, K. (1999) J. Biol. Chem. 274, 31131-31134[Abstract/Free Full Text]
18. Gong, L., Millas, S., Maul, G. G., and Yeh, E. T. H. (2000) J. Biol. Chem. 275, 3355-3359[Abstract/Free Full Text]
19. Kim, K. I., Baek, S. H., Jeon, Y-J., Nishimori, S., Suzuki, T., Uchida, S., Shimbara, N., Saitoh, H., Tanaka, K., and Chung, C. H. (2000) J. Biol. Chem. 275, 14102-14106[Abstract/Free Full Text]
20. Yeh, E. T. H., Gong, L., and Kamitani, T. (2000) Gene (Amst.) 248, 1-14[CrossRef][Medline] [Order article via Infotrieve]
21. Enjuanes, L., Carrascosa, A. L., Moreno, M. A., and Viñuela, E. (1976) J. Gen. Virol. 32, 471-477[Abstract]
22. Carrascosa, A. L., del Val, M., Santarén, J. F., and Viñuela, E. (1985) J. Virol. 54, 337-344[Medline] [Order article via Infotrieve]
23. Fuerst, T. R., Niles, E. G., Studier, F. W., and Moss, B. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8122-8126[Abstract]
24. Herlitze, S., and Koenen, M. (1990) Gene (Amst.) 91, 143-147[Medline] [Order article via Infotrieve]
25. Sanz, A., García-Barreno, B., Nogal, M. L., Viñuela, E., and Enjuanes, L. (1985) J. Virol. 54, 199-206[Medline] [Order article via Infotrieve]
26. Chirgwin, J. M., Przbyla, A. E., McDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18, 5294-5299[Medline] [Order article via Infotrieve]
27. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., pp. 7.26-7.29 and 7.79-7.83 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
28. Yáñez, R. J., Rodríguez, J. M, Salas, M. L., and Viñuela, E. (1993) J. Gen. Virol. 74, 1633-1638[Abstract]
29. Andrés, G., García-Escudero, R., Simón-Mateo, C., and Viñuela, E. (1998) J. Virol. 72, 8988-9001[Abstract/Free Full Text]
30. García-Beato, R., Freije, J. M., López-Otín, C., Blasco, R., Viñuela, E., and Salas, M. L. (1992) Virology 188, 938-947[Medline] [Order article via Infotrieve]
31. Tihanyi, K., Bourbonnière, M., Houde, A., Rancourt, C., and Weber, J. M. (1993) J. Biol. Chem. 268, 1780-1785[Abstract/Free Full Text]
32. Sircar, S., Ruzindana-Umunyana, A., Neugebauer, W., and Weber, J. M. (1998) Antiviral Res. 40, 45-51[CrossRef][Medline] [Order article via Infotrieve]
33. Almazán, F., Rodríguez, J. M., Andrés, G., Pérez, R., Viñuela, E., and Rodriguez, J. F. (1992) J. Virol. 66, 6655-6667[Abstract]
34. Salas, M. L., Rey-Campos, J., Almendral, J. M., Talavera, A., and Viñuela, E. (1986) Virology 152, 228-240[Medline] [Order article via Infotrieve]
35. Drenth, J., Kalk, K. H., and Swen, H. M. (1976) Biochemistry 15, 3731-3738[Medline] [Order article via Infotrieve]
36. Moss, B., and Rosenblum, E. N. (1973) J. Mol. Biol. 81, 267-269[Medline] [Order article via Infotrieve]
37. Weber, J. (1976) J. Virol. 17, 462-471[Medline] [Order article via Infotrieve]
38. Anderson, C. W.,. (1990) Virology 177, 259-272[Medline] [Order article via Infotrieve]
39. Kane, E. M., and Shuman, S. (1993) J. Virol. 67, 2689-2698[Abstract]
40. Cotten, M., and Weber, J. M. (1995) Virology 213, 494-502[CrossRef][Medline] [Order article via Infotrieve]
41. Greber, U. F., Webster, P., Weber, J., and Helenius, A. (1996) EMBO J. 15, 1766-1777[Abstract]
42. Higgins, D. G., Thompson, J. D., and Gibson, T. J. (1996) Methods Enzymol. 266, 383-402[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.